Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

nContact's ablation technology succeeds in study

This article was originally published in Clinica

Executive Summary

Ablation of heart tissue using technology developed by nContact Surgical (Raleigh, North Carolina) can successfully treat persistent atrial fibrillation (AF), a small-scale trial has suggested. In the study, 43 patients underwent a closed chest convergent procedure, which combines epicardial and endocardial ablation via a minimally-invasive, closed chest approach. Diagnostic endocardial mapping technology was used during the three-hour procedure to ensure complete bi-atrial ablation and to confirm procedural endpoints. The patients had suffered AF an average of eight years and had enlarged left atria; this is considered one of the more difficult patient populations to treat. After three months, 81% of the patients were free of arrhythmia recurrence. The data were presented at the annual meeting of the Heart Rhythm Society, held in Denver, Colorado, on 12-15 May.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel